A clinical study to evaluate anti-hypertensive and other health benefits of Moringa oleifera leaf extract in patients with essential hypertension

Anti-hypertensive and pleiotropic effects of Moringa oleifera leaf extract as an add-on therapy in patients with essential hypertension - A randomized double blind placebo controlled trial. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/062052

Enrollment

150

Registered

2024-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Moringa oleifera leaf extract: Moringa oleifera leaf extract 600 mg capsule thrice daily orally in addition to background standard antihypertensive agents for a period of 3 months Contr

Eligibility

Inclusion criteria

Inclusion criteria: Patients with essential hypertension aged = 18 years, irrespective of gender, with or without other comorbidities, who fulfill the following criteria: Patients on treatment with stable dose of antihypertensive agents for atleast 1 month and has not yet attained target blood pressure goals (130 mm Hg of systolic and 80 mm Hg of diastolic blood pressure) and not requiring dose escalation or addition of new anti-hypertensive agent according to clinical judgment of the treating physician.

Exclusion criteria

Exclusion criteria: Patients with secondary hypertension. Patients with resistant hypertension. Patients with hypertensive urgency or emergency. Patients not on stable dose of oral hypoglycemic drugs or insulin for past 1 month. Pregnant and lactating women, women in reproductive age group not practicing contraceptive measures. Patients with hepatic impairment (elevated liver enzymes more than 2 times upper normal limit) Patients with renal impairment (serum Creatinine more than 1.2 mg per dl) Patients with recent history of coronary artery disease Patients with peripheral vascular disease. Patients who had participated in other trials in the past three months. Patients on other herbal medications.

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in systolic blood pressure at the end of 3 monthsTimepoint: 3 months	—

Secondary

Measure	Time frame
Mean change from baseline in diastolic blood pressure, HbA1c level, oxidative stress marker and antioxidant level, hs-CRP, liver and renal function, lipid profile, serum uric acid level and endothelial function using plethysmography at the end of 3 monthsTimepoint: 3 months;Safety of Moringa oleifera leaf extract in essential hypertension patientsTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Sadish M

Jawaharlal Institute of Postgraduate Medical Education & Research

dr.harivenkatesh82@gmail.com9968856995

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026